Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis
Also, AOX supplements such as inositol, L-carnitine, ALC and CoQ10 have shown potential for women undergoing ICSI, particularly those with previous ICSI failure
Clinicians prescribing Mounjaro must be familiar with both the clinical presentation of adverse effects and their appropriate documentation
Semaglutide is a GLP-1 receptor agonist, while tirzepatide is both a GIP and GLP-1 receptor agonist
Rotate sites, avoid compromised skin, stick to a weekly schedule, and follow the guidance of your provider